<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190510043545N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-06</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>the effect of ventilator settings on diaphragm atrophy</public_title>
      <acronym></acronym>
      <scientific_title>the effect of ventilator settings based on diaphragm thickening fraction on diaphragm atrophy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69304</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The Random allocation rule is the simplest method of limited randomization. This method represents a large block for the entire sample size, which means that the balance in the number of people allocated to each group will be achieved at the end of the study. For this purpose, the researchers first determined a total sample size (40 people) and then randomly assigned groups of them to group A and the rest to group B.
For example, in a study with a sample size of 40 people, 20 balls for the intervention group A and 20 balls for the control group B are placed in a lottery container, and then the balls are randomly removed from the container without replacement and the created sequence is recorded.
It should be noted that random sequence generation will be done through randomization.com
Allocation Concealment: Sealed envelopes
Randomization Unit: Individual, Blinding description: In this study, the researcher and the outcome evaluator do not know the group in which the patients are located.
In this study, the data analyst does not know the group in which the patients are located.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diaphragm atrophy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the normal settings of the ventilator on pcv (pressure control ventilation)  mode, the ventilator is set based on DTF. If the DTF (diaphragm thickening fraction) is above 30%, the inspiratory pressure increases, and if it is less than 15%, the inspiratory pressure decreases. In this study, in the intervention group, diaphragm ultrasonography is performed every day and DTF is calculated, if the DTF is above 30%, in the same interval, the tidal volume is created at 6 to 8 cc/kg; Increased inspiratory pressure (settings tend to 8 cc/kg) and if the DTF is less than 15%, in the same range; Inspiratory pressure decreases. (settings tend to 6 cc/kg). Intervention 2: Control group: The control group uses the usual settings of the ventilator. In the usual settings of the ventilator in the PCV mode (pressure control ventilation ) , the inspiratory pressure is set so that the patient has a tidal volume between 6 and 8 ml/kg. And the  peak inspiratory pressure should not increase from 30 h2o cm.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about the outcomes of the study is published in a research paper

When:
At the same time as the article is published

To whom:
Researchers working in academic and scientific institutions

Conditions:
Analysis for review articles and meta-analysis

Where to obtain:
Correspond to this email:
sjvdpurafzali@yahoo.com

How to obtain:
These items should be clearly explained in the requested email:
- How to use information
- The details of the research that wants to use this information.
- Detailed information of the applicant
After reviewing these items, an answer will be given immediately

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Javad Purafzali Firuzabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza hospital-Imam Reza Square, Ibn-e Sina Avenue, Mashhad - Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913316</zip>
        <telephone>+98 936 624 9277</telephone>
        <email>sjvdpurafzali@yahoo.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Javad Purafzali Firuzabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam Reza hospital-Imam Reza Square, Ibn-e Sina Avenue, Mashhad - Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913316</zip>
        <telephone>+98 936 624 9277</telephone>
        <email>sjvdpurafzali@yahoo.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Over 18 years
with informed consent (from family)
The patient has been intubated in the last 24 hours.
be on (pressure controlled ventilator mode).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Absence of underlying diseases (like: lung disease, myopathy, brain disease, connective tissue disease)
No poisoning with things that cause muscle paralysis.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J95.850</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mechanical complication of respirator</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the normal settings of the ventilator on pcv (pressure control ventilation)  mode, the ventilator is set based on DTF. If the DTF (diaphragm thickening fraction) is above 30%, the inspiratory pressure increases, and if it is less than 15%, the inspiratory pressure decreases. In this study, in the intervention group, diaphragm ultrasonography is performed every day and DTF is calculated, if the DTF is above 30%, in the same interval, the tidal volume is created at 6 to 8 cc/kg; Increased inspiratory pressure (settings tend to 8 cc/kg) and if the DTF is less than 15%, in the same range; Inspiratory pressure decreases. (settings tend to 6 cc/kg)</i_keyword>
      <i_keyword>Control group: The control group uses the usual settings of the ventilator. In the usual settings of the ventilator in the PCV mode (pressure control ventilation ) , the inspiratory pressure is set so that the patient has a tidal volume between 6 and 8 ml/kg. And the  peak inspiratory pressure should not increase from 30 h2o cm.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Diaphragm Thickness. Timepoint: daily for 3 days. Method of measurement: Ultrasonography.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Diaphragm thickening fraction. Timepoint: Daily for 3 days. Method of measurement: Ultrasonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-02-28</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Imam Reza hospital-Imam Reza Square, Ibn-e Sina Avenue, Mashhad - Iran Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
